COVID-19 Vaccine Janssen |
COVID-19 vaccine (Ad26.COV2-S [recombinant]) |
adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S) |
EMEA/H/C/005737 |
Janssen-Cilag International NV |
2021/03/11
|
Authorised |
Heplisav B |
hepatitis B surface antigen |
hepatitis B surface antigen |
EMEA/H/C/005063 |
Dynavax GmbH |
2021/02/18
|
Authorised |
Ogluo |
glucagon |
Glucagon |
EMEA/H/C/005391 |
Xeris Pharmaceuticals Ireland Limited |
2021/02/11
|
Authorised |
Yuflyma |
adalimumab |
adalimumab |
EMEA/H/C/005188 |
Celltrion Healthcare Hungary Kft. |
2021/02/11
|
Authorised |
Tukysa |
tucatinib |
Tucatinib |
EMEA/H/C/005263 |
Seagen B.V. |
2021/02/11
|
Authorised |
Lenalidomide Krka |
lenalidomide |
lenalidomide hydrochloride monohydrate |
EMEA/H/C/005734 |
Krka, d.d., Novo mesto |
2021/02/11
|
Authorised |
Lenalidomide Krka d.d. Novo mesto |
lenalidomide |
lenalidomide hydrochloride monohydrate |
EMEA/H/C/005348 |
Krka, d.d., Novo mesto |
2021/02/11
|
Authorised |
Lenalidomide Krka d.d. |
lenalidomide |
lenalidomide hydrochloride hydrate |
EMEA/H/C/005729 |
Krka, d.d., Novo mesto |
2021/02/11
|
Authorised |
Lumoxiti |
moxetumomab pasudotox |
Moxetumomab pasudotox |
EMEA/H/C/005322 |
AstraZeneca AB |
2021/02/08
|
Authorised |
Inrebic |
fedratinib |
fedratinib dihydrochloride monohydrate |
EMEA/H/C/005026 |
Celgene Europe BV |
2021/02/08
|
Authorised |
Kixelle |
insulin aspart |
insulin aspart |
EMEA/H/C/004965 |
Mylan IRE Healthcare Limited |
2021/02/05
|
Authorised |
Rukobia |
fostemsavir |
fostemsavir trometamol |
EMEA/H/C/005011 |
ViiV Healthcare B.V. |
2021/02/04
|
Authorised |
Vaxzevria (previously COVID-19 Vaccine AstraZeneca) |
COVID-19 Vaccine (ChAdOx1-S [recombinant]) |
ChAdOx1-SARS-COV-2 |
EMEA/H/C/005675 |
AstraZeneca AB |
2021/01/29
|
Authorised |
Enhertu |
trastuzumab deruxtecan |
trastuzumab deruxtecan |
EMEA/H/C/005124 |
Daiichi Sankyo Europe GmbH |
2021/01/18
|
Authorised |
Onbevzi |
bevacizumab |
bevacizumab |
EMEA/H/C/005640 |
Samsung Bioepis NL B.V. |
2021/01/11
|
Authorised |
Elzonris |
tagraxofusp |
tagraxofusp |
EMEA/H/C/005031 |
Stemline Therapeutics B.V. |
2021/01/07
|
Authorised |
Xofluza |
baloxavir marboxil |
Baloxavir marboxil |
EMEA/H/C/004974 |
Roche Registration GmbH |
2021/01/07
|
Authorised |
Roclanda |
latanoprost / netarsudil |
Latanoprost, Netarsudil mesilate |
EMEA/H/C/005107 |
Aerie Pharmaceuticals Ireland Limited |
2021/01/07
|
Authorised |
COVID-19 Vaccine Moderna |
COVID-19 mRNA Vaccine (nucleoside modified) |
CX-024414 (single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2) |
EMEA/H/C/005791 |
Moderna Biotech Spain, S.L. |
2021/01/06
|
Authorised |
Comirnaty |
COVID-19 mRNA vaccine (nucleoside-modified) |
Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 |
EMEA/H/C/005735 |
BioNTech Manufacturing GmbH |
2020/12/21
|
Authorised |